AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA [3]) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with K i values of …

ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans -∆ 9 …

This substance is included in Schedule II of the 1971 Convention on Psychotropic Substances.

FUB-AMB, an indazole carboxamide synthetic cannabinoid recreational drug, was one of the compounds most frequently reported to governmental agencies worldwide between 2016 and …

AB-FUBINACA (AMB-FUBINACA [2]) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with K i values of 0.9 nM at CB 1 and 23.2 nM at CB 2 and EC 50 …

FUB-AMB can be differentiated from its ortho and meta fluoro positional isomers 1 and 2 based on the splitting pattern of the proton signals for the phenyl ring. For FUB-AMB, the fluoro …

2017年1月19日 · AMB-FUBINACA is an example of the emerging class of “ultrapotent” synthetic cannabinoids and poses a public health concern. Collaboration among clinical laboratory staff, …

2015年11月13日 · FUB-AMB is an analogue of AB-FUBINACA, a potent synthetic cannabinoid first synthesized by Pfizer. AB-FUBINACA exhibits a strong affinity (Ki =0.9 nM) for the CB1 …

acute administration of FUB-AMB has the potential to produce severe adverse reactions in humans up to, and including, death. The most predominant symptom in a cluster of confirmed …

On November 3, 2017, DEA published an order in the Federal Register amending 21 CFR 1308.11 (h) to temporarily place methyl 2- (1- (4-fluorobenzyl)-1 H -indazole-3-carboxamido)-3 …